Yemaachi Biotech, a cancer research and diagnostics firm with headquarters in Washington, DC, has raised a $3 million initial investment to further its goal of worldwide accuracy oncology diversification.
LifeLine Family Heritage Fund, Y Combinator, Tencent, LoftyInc Capital, VestedWorld, V Square Capital, and Ethan Perlstein were among the investors in the round, which was led by V8 Capital.
Yaw Bediako, David Hutchful, Joyce Ngoi, and Yaw Attua-Afari formed Yemaachi in 2020 with the goal of enhancing precision oncology across Africa and beyond by increasing access to research and diagnostics.
Yemaachi’s first-of-its-kind pan-African genomic and clinical expertise and experience and research platform, as well as broad clinical contacts across Africa, paving the way for ground-breaking products and partnerships focused on developing new molecular diagnostics and therapeutic targets.
Yemaachi’s co-founder and CEO, Yaw Bediako, Ph.D., stated that they had merely touched the surface of genomic data and comprehension. They understand that genetic consequences, including those inside the genome, are context-dependent.
As a component of the Calestous Juma Science Leadership Fellowship granted to Bediako, Yemaachi was currently chosen as a recipient of a $1 million grant from the Bill & Melinda Gates Foundation. The prestigious fellowship is designed to help scientists make solutions to key global health issues.
